Evidence map›Paper›PMID 33896471›Full record

ReviewSeminars in nephrology2021

Opioids in Hemodialysis Patients.

Sahir Kalim, Karen S Lyons, Sagar U Nigwekar

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Seminars in nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Sahir KalimDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Karen S LyonsWilliam F. Connell School of Nursing, Boston College, Boston, MA.
Sagar U NigwekarDivision of Nephrology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA. Electronic address: snigwekar@mgh.harvard.edu.

Funding

Reducing Chronic Pain and Opioid Use in Hemodialysis PatientsU01DK123818 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KALIM, SAHIR, NIGWEKAR, SAGAR · 2019 to 2019
$2.4M
Protein Carbamylation and the Progression and Complications of CKDR01DK124453 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KALIM, SAHIR · 2020 to 2022
$843k
The effects of protein carbamylation in end stage kidney diseaseK23DK106479 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI KALIM, SAHIR · 2015 to 2019
$789k
NIDDK NIH HHS K23 DK106479NIDDK NIH HHS R01 DK124453NIDDK NIH HHS U01 DK123818
6 · The paper itself

Abstract

Chronic pain and prescription opioid use are prevalent among patients with end-stage kidney disease treated with hemodialysis. Vulnerabilities to complications from opioid use are high in this patient population, as shown in many recent, well-conducted, patient-oriented studies. Such studies have highlighted the need for a balanced approach to pain management in hemodialysis patients that includes careful assessment of the risks and benefits of opioid prescriptions in this population. In this article, we review the available literature and experience regarding opioid prescriptions among hemodialysis patients, discuss clinical implications, and outline ongoing research.

Indexed as

Analgesics, OpioidChronic PainHumansPain ManagementRenal DialysisAnalgesics, OpioidBuprenorphinehemodialysishydrocodonemethadonemorphineopioidoxycodonepain

Identifiers

PMID33896471
PMCPMC8083988

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.